-

01:21:05 AM

LIVE Real Time CRNX Stock Market News

CRNX - Crinetics Pharmaceuticals Inc

04/12/21 4:05 PM

Nasdaq : CRNX

Crinetics Pharmaceuticals Announces Closing of Common Stock Offering

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today that it

RHEA-AI

neutral

04/07/21 6:31 PM

Nasdaq : CRNX

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today the

RHEA-AI

neutral

03/30/21 4:05 PM

Nasdaq : CRNX

Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results

Advancing paltusotine into a Phase 3 program for acromegaly following an FDA meeting Phase 1 clinical proof-of-concept data for CRN04894 and CRN04777 expected in 1H 2021 and mid-2021, respectively Management hosting webcast and conference call today at 4:30 p.m. ET SAN DIEGO, March 30, 2021

RHEA-AI

very positive

03/24/21 7:10 AM

Nasdaq : CRNX

Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel

RHEA-AI

neutral

03/22/21 7:10 AM

Nasdaq : CRNX

Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and

RHEA-AI

neutral

03/12/21 7:10 AM

Nasdaq : CRNX

Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs

RHEA-AI

neutral

02/04/21 7:10 AM

Nasdaq : CRNX

Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing's Disease (CRN04894) Advances into Phase 1 Study

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that

RHEA-AI

neutral

02/03/21 7:10 AM

Nasdaq : CRNX

Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and

RHEA-AI

neutral

01/06/21 7:05 AM

Nasdaq : CRNX

Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference

- Paltusotine planned to advance to a pivotal Phase 3 trial in acromegaly in H1 2021 - - Initiation of Phase 1 proof-of-concept study evaluating CRN04894 for the treatment of congenital adrenal hyperplasia and Cushing's disease expected in January 2021 - - Initiation of Phase 1 proof-of-concept

RHEA-AI

positive

11/23/20 7:30 AM

Nasdaq : CRNX

Crinetics Pharmaceuticals to Participate in December Investor Conferences

Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that company management will participate in the following conferences in the month of December. Please see additional details below: Evercore ISI 3 rd Annual HealthCONx Conference Date:

RHEA-AI

neutral